SC 13D/A | 2024-03-15 | Flynn James E | Larimar Therapeutics, Inc. | 6,151,389 | 9.6% | EDGAR |
SC 13G | 2024-02-26 | RA CAPITAL MANAGEMENT, L.P. | Larimar Therapeutics, Inc. | 6,045,351 | 9.5% | EDGAR |
SC 13D/A | 2024-02-16 | Flynn James E | Larimar Therapeutics, Inc. | 6,151,389 | 10.1% | EDGAR |
SC 13D/A | 2024-02-15 | Flynn James E | Larimar Therapeutics, Inc. | 4,721,183 | 10.8% | EDGAR |
SC 13G/A | 2024-02-14 | PERCEPTIVE ADVISORS LLC | Larimar Therapeutics, Inc. | 0 | 0.0% | EDGAR |
SC 13G | 2024-02-14 | Verition Fund Management LLC | Larimar Therapeutics, Inc. | 2,811,131 | 6.4% | EDGAR |
SC 13G | 2024-02-14 | Blue Owl Capital Holdings LP | Larimar Therapeutics, Inc. | 3,414,468 | 7.8% | EDGAR |
SC 13G/A | 2024-02-13 | JANUS HENDERSON GROUP PLC | Larimar Therapeutics, Inc. | 2,641,065 | 6.0% | EDGAR |
SC 13G | 2023-08-18 | JANUS HENDERSON GROUP PLC | Larimar Therapeutics, Inc. | 2,191,411 | 5.1% | EDGAR |
SC 13D/A | 2023-03-17 | Flynn James E | Larimar Therapeutics, Inc. | 4,721,183 | 10.9% | EDGAR |
SC 13G | 2023-02-14 | PERCEPTIVE ADVISORS LLC | Larimar Therapeutics, Inc. | 2,860,000 | 6.6% | EDGAR |
SC 13G/A | 2023-02-13 | CHI Advisors LLC | Larimar Therapeutics, Inc. | 3,473,366 | 8.0% | EDGAR |
SC 13G/A | 2023-01-23 | Opaleye Management Inc. | Larimar Therapeutics, Inc. | 1,560,000 | 3.6% | EDGAR |
SC 13G/A | 2022-11-14 | RA CAPITAL MANAGEMENT, L.P. | Larimar Therapeutics, Inc. | 0 | 0.0% | EDGAR |
SC 13D/A | 2022-09-16 | Flynn James E | Larimar Therapeutics, Inc. | 4,721,183 | 11.8% | EDGAR |
SC 13G | 2022-02-18 | Opaleye Management Inc. | Larimar Therapeutics, Inc. | 943,702 | 5.3% | EDGAR |
SC 13G/A | 2022-02-15 | ACUTA CAPITAL PARTNERS, LLC | Larimar Therapeutics, Inc. | 0 | 0.0% | EDGAR |
SC 13G/A | 2022-02-14 | RA CAPITAL MANAGEMENT, L.P. | Larimar Therapeutics, Inc. | 1,334,610 | 7.5% | EDGAR |
SC 13G/A | 2022-02-11 | ORBIMED ADVISORS LLC | Larimar Therapeutics, Inc. | 0 | 0.0% | EDGAR |
SC 13G/A | 2022-02-11 | CHI Advisors LLC | Larimar Therapeutics, Inc. | 1,515,148 | 8.6% | EDGAR |